Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 7, 2023; 29(1): 126-143
Published online Jan 7, 2023. doi: 10.3748/wjg.v29.i1.126
Management of metabolic-associated fatty liver disease: The diabetology perspective
Mohammad Sadiq Jeeyavudeen, Shahanas K A Khan, Sherouk Fouda, Joseph M Pappachan
Mohammad Sadiq Jeeyavudeen, Department of Endocrinology and Metabolism, University Hospitals of Edinburgh, Edinburgh EH4 2XU, United Kingdom
Shahanas K A Khan, Joseph M Pappachan, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom
Sherouk Fouda, School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC 3046, Australia
Joseph M Pappachan, Faculty of Science, Manchester Metropolitan University, Manchester M15 6BH, United Kingdom
Joseph M Pappachan, Faculty of Biology, University of Manchester, Manchester M13 9PL, United Kingdom
Author contributions: Jeeyavudeen MS substantially contributed to literature search, interpretation of relevant literature, article drafting, revision and Figure preparation; Khan SKA and Fouda S contributed to the interpretation of relevant literature, and article drafting; Pappachan JM contributed to the conception and design of the article, literature search and revision of the article critically for important intellectual content; All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: The authors have nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Joseph M Pappachan, FRCP, MD, Professor, Senior Editor, Senior Researcher, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom.
Received: September 20, 2022
Peer-review started: September 20, 2022
First decision: November 26, 2022
Revised: November 26, 2022
Accepted: December 13, 2022
Article in press: December 13, 2022
Published online: January 7, 2023
Core Tip

Core Tip: The prevalence of metabolic-associated fatty live disease (MAFLD) and type 2 diabetes mellitus (T2DM) has increased exponentially as a consequence of the obesity pandemic across the globe. The pathobiology of T2DM and MAFLD are similar because both these disorders occur as a consequence of metabolic syndrome, and often coexist in many patients potentiating adverse outcomes and progression of individual diseases. However, the awareness about this coexistence is still inadequate even among hepatologists and diabetologists. A multidisciplinary team approach involving both the specialists is crucial in the optimal and wholistic management of both the disorders which is the theme of this comprehensive review.